# Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension

> **NCT00219037** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 1955 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** aliskiren

## Key facts

- **NCT ID:** NCT00219037
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 1955 (ACTUAL)
- **Last updated:** 2011-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00219037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00219037, "Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00219037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*